Dose–Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type 1 in Released-Active Form in the Light–Dark Test in Mice
Kardash E. V., Ertuzun I. A., Khakimova G. R., Kolyadin A. N., Tarasov S. A., Wagner S., Andriambeloson E., Ivashkin V. T., Epstein O. I.
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1177/1559325818779752
Аннотация:
Earlier studies have shown that combination of antibodies to S100 protein and to cannabinoid receptor type 1 in released-active form (Brizantin) may possess anxiolytic properties and decrease nicotine dependence. Released-active form of antibodies is a novel approach that permits to modify natural functions of the target molecule (antigen) under investigation. The aim of the present study was to evaluate the anxiolytic-like effect of Brizantin in the light–dark test in mice, according to its ability to influence the number of entries into the lit compartment and the total time spent there. Three doses of Brizantin (2.5, 5, and 10 mL/kg) were compared with diazepam (1 mg/kg), placebo, and vehicle control. Anxiolytic-like effect of the tested drug was shown to be dose dependent, with an increasing trend from 2.5 to 10 mL/kg. Brizantin in its highest dose significantly increased studied behavioral parameters, although its effect was less pronounced than that of the reference drug diazepam
Ключевые слова:
animal model; antibody-based drugs; anxiety; cannabinoid receptor antagonists; dose–response; mice; nicotine addiction; released-activity; S100 protein
Язык текста: Английский
ISSN: 1559-3258
Kardash E. V.
Ertuzun I. A.
Khakimova G. R.
Kolyadin A. N.
Tarasov S. A.
Wagner S.
Andriambeloson E.
Ivashkin V. T. Vladimir Trofimovich 1939-
Epstein O. I.
Кардаш Е. В.
Ертюзун И. А.
Хакимова Г. Р.
Колядин А. Н.
Тарасов С. А.
Wагнер С.
Андриамбелосон Е.
Ивашкин В. Т. Владимир Трофимович 1939-
Епстеин О. И.
Dose–Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type 1 in Released-Active Form in the Light–Dark Test in Mice
Текст визуальный непосредственный
Dose-Response
Vol.16, Issue2
2018
Статья
animal model antibody-based drugs anxiety cannabinoid receptor antagonists dose–response mice nicotine addiction released-activity S100 protein
Earlier studies have shown that combination of antibodies to S100 protein and to cannabinoid receptor type 1 in released-active form (Brizantin) may possess anxiolytic properties and decrease nicotine dependence. Released-active form of antibodies is a novel approach that permits to modify natural functions of the target molecule (antigen) under investigation. The aim of the present study was to evaluate the anxiolytic-like effect of Brizantin in the light–dark test in mice, according to its ability to influence the number of entries into the lit compartment and the total time spent there. Three doses of Brizantin (2.5, 5, and 10 mL/kg) were compared with diazepam (1 mg/kg), placebo, and vehicle control. Anxiolytic-like effect of the tested drug was shown to be dose dependent, with an increasing trend from 2.5 to 10 mL/kg. Brizantin in its highest dose significantly increased studied behavioral parameters, although its effect was less pronounced than that of the reference drug diazepam